Fennec Pharmaceuticals (FENC) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Zura Bio (ZURA) over the past year, gaining 14.8% versus a loss of 11.3%. Zura Bio is the larger company by market cap ($383.3 million vs $375.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | ZURA |
|---|---|---|
| Share price | $10.71 | $4.00 |
| Market cap | $375.57M | $383.32M |
| 1-day change | +0.75% | -3.15% |
| YTD return | +39.09% | -23.66% |
| 1-year return | +14.79% | -11.31% |
| 5-year return | +16.54% | — |
| Forward P/E | 11.30 | — |
| EPS (TTM) | $-0.12 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.25 | $7.44 |
| 52-week low | $5.65 | $3.15 |
| Distance from 52-week high | -19.17% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +64.99% | +350.00% |
| Average volume | 191.88K | 1.44M |
| Shares outstanding | 35.07M | 95.83M |
| Employees | 35 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed ZURA by 26.1 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
FENC vs ZURA FAQ
Which is bigger, Fennec Pharmaceuticals or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $375.57M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, FENC or ZURA?
FENC returned +14.79% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.